George R. Blumenschein

Overview

Best Publications

• Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

  H. Borghaei;L. Paz-Ares;L. Horn;D. R. Spigel

  9411
  Citations

• Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

  Robert L. Ferris;George Blumenschein;Jerome Fayette;Joel Guigay

  4492
  Citations

• First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

  David P. Carbone;Martin Reck;Luis Paz-Ares;Benjamin Creelan

  2456
  Citations

• Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study

  Jeffrey D. Bradley;Rebecca Paulus;Ritsuko Komaki;Gregory Masters

  2299
  Citations

• An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

  Lauren Averett Byers;Lixia Diao;Jing Wang;Pierre Saintigny

  1270
  Citations

• Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study.

  Daniel R. Gomez;Chad Tang;Jianjun Zhang;George R. Blumenschein

  1212
  Citations

• Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study

  Daniel R Gomez;George R Blumenschein;J Jack Lee;Mike Hernandez

  1151
  Citations

• Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion.

  Sewa S. Legha;Robert S. Benjamin;Bruce Mackay;Michael Ewer

  1040
  Citations

• The BATTLE Trial: Personalizing Therapy for Lung Cancer

  Edward S. Kim;Roy S. Herbst;Ignacio Ivan Wistuba;Jiun-Kae Jack Lee

  1023
  Citations

• Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.

  Robert L. Ferris;George Blumenschein;Jerome Fayette;Joel Guigay

  778
  Citations

• Phase I/II Trial Evaluating the Anti-Vascular Endothelial Growth Factor Monoclonal Antibody Bevacizumab in Combination With the HER-1/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib for Patients With Recurrent Non–Small-Cell Lung Cancer

  Roy S. Herbst;David H. Johnson;Eric Mininberg;David P. Carbone

  773
  Citations

• Leukocyte Interferon-Induced Tumor Regression in Human Metastatic Breast Cancer, Multiple Myeloma, and Malignant Lymphoma

  Jordan U. Gutterman;George R. Blumenschein;Raymond Alexanian;Hwee-Yong Yap

  762
  Citations

• Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial.

  Tina Cascone;William N. William;Annikka Weissferdt;Cheuk H. Leung

  574
  Citations

• Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome

  Nathan T. Ihle;Lauren Averett Byers;Edward S. Kim;Pierre Saintigny

  558
  Citations

• Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

  David R. Spigel;Thomas J. Ervin;Rodryg A. Ramlau;Davey B. Daniel

  524
  Citations

• Pathological Assessment of Response to Induction Chemotherapy in Breast Cancer

  Lorne D. Feldman;Gabriel N. Hortobagyi;Aman U. Buzdar;Frederick C. Ames

  471
  Citations

• Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases

  Everett E. Vokes;N. Ready;E. Felip;L. Horn

  444
  Citations

• Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer.

  Jeffrey D. Bradley;Chen Hu;Ritsuko R. Komaki;Gregory A. Masters

  438
  Citations

• Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial

  Kevin J Harrington;Robert L Ferris;George Blumenschein;A Dimitrios Colevas

  437
  Citations

• Early and delayed clinical cardiotoxicity of doxorubicin.

  Aman U. Buzdar;Connie Marcus;George R. Blumenschein;Terry L. Smith

  424
  Citations